Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY
October 19, 2015 6:42 AM EDTOppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00), following the company's Oct. 15th announcement of a licensing agreement for FPA008 with BMY. FPRX will receive $350M cash upfront and is eligible for an additional $1.39B in development/regulatory... More
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM EDTLeerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM EDTLeerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More
Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)
October 15, 2015 9:20 AM EDTFive Prime Therapeutics, Inc.(Nasdaq: FPRX) shares are ripping early following news that the company entered an... More
Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb (BMY) Worth Up to $1.74B
October 15, 2015 6:06 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Five Prime Therapeutics, Inc.(Nasdaq: FPRX) today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibbs programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor... More
